NZ336381A - Formulation and method for treating neoplasms by inhalation - Google Patents

Formulation and method for treating neoplasms by inhalation

Info

Publication number
NZ336381A
NZ336381A NZ336381A NZ33638197A NZ336381A NZ 336381 A NZ336381 A NZ 336381A NZ 336381 A NZ336381 A NZ 336381A NZ 33638197 A NZ33638197 A NZ 33638197A NZ 336381 A NZ336381 A NZ 336381A
Authority
NZ
New Zealand
Prior art keywords
inhalation
formulation
treating neoplasms
neoplasms
treating
Prior art date
Application number
NZ336381A
Other languages
English (en)
Inventor
Michael E Placke
Anthony R Imondi
Michael J Brooker
John E Frye
Praful K Shah
Douglas R Flanagan
Maureen D Donovan
Original Assignee
Battelle Memorial Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute filed Critical Battelle Memorial Institute
Publication of NZ336381A publication Critical patent/NZ336381A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ336381A 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation NZ336381A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3378996P 1996-12-30 1996-12-30
PCT/US1997/024289 WO1998029110A2 (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation

Publications (1)

Publication Number Publication Date
NZ336381A true NZ336381A (en) 2000-11-24

Family

ID=21872447

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336381A NZ336381A (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation

Country Status (12)

Country Link
US (5) US6471943B1 (enExample)
EP (1) EP0954283B1 (enExample)
JP (1) JP2001513078A (enExample)
CN (1) CN1245423A (enExample)
AT (1) ATE357214T1 (enExample)
AU (1) AU741439B2 (enExample)
BR (1) BR9713661A (enExample)
CA (2) CA2275889C (enExample)
DE (1) DE69737510T2 (enExample)
ES (1) ES2285743T3 (enExample)
NZ (1) NZ336381A (enExample)
WO (1) WO1998029110A2 (enExample)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2346029A1 (en) * 1998-10-02 2000-04-13 Anthony R. Imondi Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
WO2000045805A2 (en) * 1999-02-08 2000-08-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
WO2001056596A1 (en) 2000-02-04 2001-08-09 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
CN1431919A (zh) * 2000-04-03 2003-07-23 巴特勒记忆研究所 装置和制剂
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
EP1424898A4 (en) * 2001-08-20 2008-04-02 Transave Inc TREATMENT OF CANCER BY INHALATION OF STABLE FORMULATIONS CONTAINING PLATINUM
CA2461556A1 (en) * 2001-10-15 2003-04-24 Crititech, Inc. Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
CN101570764A (zh) * 2001-10-19 2009-11-04 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
CA2474508A1 (en) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2477982A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
ITPI20020018A1 (it) * 2002-03-28 2002-06-26 Azienda Ospedaliera Pisana Ventilazione polmonare a variazione di flusso
GB0208516D0 (en) * 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7677411B2 (en) * 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
US6985798B2 (en) 2002-05-10 2006-01-10 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
US7118010B2 (en) 2002-05-10 2006-10-10 Oriel Therapeutics, Inc. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
EP1534366B1 (en) * 2002-06-27 2014-01-08 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
JP2006502233A (ja) * 2002-08-02 2006-01-19 トランセーブ，インク． 白金凝集物およびその製造方法
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
ES2539591T3 (es) * 2002-10-29 2015-07-02 Insmed Incorporated Liberación sostenida de antiinfectantes
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US20060179491A1 (en) * 2002-11-12 2006-08-10 Brian Graham Process for treating non-human animals
US7353533B2 (en) 2002-12-18 2008-04-01 Novell, Inc. Administration of protection of data accessible by a mobile device
US7185650B2 (en) * 2002-12-19 2007-03-06 Arie Huber Systems and methods for determining a minimum effective dose of an inhaled drug for an individual patient at a given time
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20040187864A1 (en) * 2003-03-24 2004-09-30 Cindet, Llc Inhalation device and method
JP2007516149A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド 基板温度の均一性を制御する方法、および、内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
ES2344899T3 (es) * 2003-09-25 2010-09-09 Astellas Pharma Inc. Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
US7377277B2 (en) * 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
US7451761B2 (en) * 2003-10-27 2008-11-18 Oriel Therapeutics, Inc. Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US20050249822A1 (en) * 2004-03-18 2005-11-10 Transave, Inc. Administration of cisplatin by inhalation
EP1755623A4 (en) * 2004-05-21 2007-10-17 Transave Inc TREATMENT OF LUNG DISEASES AND BEFORE A PULMONARY DISEASE
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1781360A1 (en) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
US20060246124A1 (en) * 2004-11-08 2006-11-02 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
US20060228405A1 (en) * 2005-04-07 2006-10-12 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
US20090180964A1 (en) * 2005-06-24 2009-07-16 Rao Papineni Transmucosal delivery of optical, spect, multimodal,drug or biological cargo laden nanoparticle(s) in small animals or humans
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
CN101360492A (zh) * 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
DK2124638T3 (en) 2007-02-26 2017-03-20 Heartbeet Ltd COMPOSITION INCREASING PERFORMANCE AND USING IT
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
US20100196455A1 (en) * 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
JP5570996B2 (ja) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド エアロゾル化可能な食料品の送達
BRPI0920655A2 (pt) * 2008-10-07 2019-07-09 Rexahn Pharmaceuticals Inc conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos
AU2010306917B2 (en) 2009-10-13 2014-11-27 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
WO2013177226A1 (en) 2012-05-21 2013-11-28 Insmed Incorporated Systems for treating pulmonary infections
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
WO2014081887A1 (en) 2012-11-20 2014-05-30 Spectrum Pharmaceuticals Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
EP3915369A1 (en) * 2012-12-13 2021-12-01 CytRx Corporation Anthracycline formulations
CN113842392A (zh) 2013-06-05 2021-12-28 西特克斯公司 用于治疗癌症的细胞毒素剂
CA2919837A1 (en) * 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
US20150265582A1 (en) 2014-02-11 2015-09-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015154084A1 (en) 2014-04-04 2015-10-08 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
ES2755941T3 (es) 2014-05-15 2020-04-24 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CA3026452C (en) 2015-06-04 2023-03-21 Crititech, Inc. Nozzle assembly and methods for use
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
JP7001593B2 (ja) 2015-08-11 2022-01-19 コグノア， インコーポレイテッド 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
SG11201808125RA (en) 2016-04-04 2018-10-30 Crititech Inc Methods for solid tumor treatment
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
US10874768B2 (en) * 2017-01-20 2020-12-29 Covidien Lp Drug eluting medical device
EP3580700A4 (en) * 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
US20220254461A1 (en) * 2017-02-09 2022-08-11 Cognoa, Inc. Machine learning algorithms for data analysis and classification
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
KR102785528B1 (ko) 2019-03-22 2025-03-21 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery
WO2021040673A1 (en) * 2019-08-26 2021-03-04 Alain Martin Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd
CN111067879B (zh) * 2020-01-20 2022-08-09 珠海瑞思普利医药科技有限公司 一种抗肿瘤组合物吸入粉雾剂及其制备方法
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246399A (en) 1977-03-21 1981-01-20 Interx Research Corporation Complexes of doxorubicin exhibiting enhanced stability
JPS5795920A (en) 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
GB8519452D0 (en) 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
US5124318A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4826817A (en) 1986-02-07 1989-05-02 Brown Thomas E Amino acid and hydroxyamino acid transporter compounds for therapeutic applications, process and use
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5115971A (en) 1988-09-23 1992-05-26 Battelle Memorial Institute Nebulizer device
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5171737A (en) 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
CA2058764A1 (en) 1989-04-28 1990-10-29 Peter D. Hodson Dry powder inhalation device
DE69033487T2 (de) 1989-12-20 2000-06-29 Autoimmune, Inc. Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5348946A (en) 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
US5681812A (en) 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5283383A (en) 1992-02-13 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Antitumor compound, compositions and method of use
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
US5622960A (en) 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
AU1875292A (en) 1992-05-04 1993-11-29 Adria Laboratories Inc. Methods for treating cancer using high-dose epirubicin
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
EP0674510B1 (en) 1992-11-27 1998-08-05 Napro Biotherapeutics, Inc. Injectable composition comprising paclitaxel
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
EP0673240B1 (en) 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
US5591737A (en) 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5594139A (en) 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JPH08301762A (ja) * 1995-05-12 1996-11-19 Teijin Ltd 肺癌治療剤
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Also Published As

Publication number Publication date
US6419901B2 (en) 2002-07-16
AU7097598A (en) 1998-07-31
DE69737510T2 (de) 2007-12-06
US20010036444A1 (en) 2001-11-01
EP0954283B1 (en) 2007-03-21
DE69737510D1 (de) 2007-05-03
ES2285743T3 (es) 2007-11-16
CA2275889C (en) 2008-03-18
US6419900B2 (en) 2002-07-16
CN1245423A (zh) 2000-02-23
US6471943B1 (en) 2002-10-29
ATE357214T1 (de) 2007-04-15
AU741439B2 (en) 2001-11-29
CA2628857A1 (en) 1998-07-09
US20010038827A1 (en) 2001-11-08
BR9713661A (pt) 2000-10-24
US20020155066A1 (en) 2002-10-24
EP0954283A2 (en) 1999-11-10
US6348209B2 (en) 2002-02-19
US20010038826A1 (en) 2001-11-08
CA2628857C (en) 2011-09-13
WO1998029110A3 (en) 1999-04-15
JP2001513078A (ja) 2001-08-28
WO1998029110A2 (en) 1998-07-09
CA2275889A1 (en) 1998-07-09

Similar Documents

Publication Publication Date Title
NZ336381A (en) Formulation and method for treating neoplasms by inhalation
WO2001066103A3 (en) Treatment of neoplasms by inhalation of carboplatin
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
EP1275381A4 (en) SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION
AU1534699A (en) Osmotic dosage form comprising first and second coats
AU3805195A (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
MX9710228A (es) Nuevos analogos de camptotecina, procedimientos de preparacion, su aplicacion como medicinas y las composiciones farmaceuticas que los comprenden.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CA2277824A1 (en) Dosage composition for nasal delivery and method of use of the same
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
ATE235893T1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
HUP9801250A3 (en) Macrocyclic 3,4-bis(3,31-indolyl)-pyrrole-2,5-dione derivatives, process for their preparation and pharmaceutical compositions containing them
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
MXPA02011247A (es) Quimioterapia de combinacion.
PL313223A1 (en) Nigella sativa as a therapeutic agent
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
Punt New drugs in the treatment of colorectal carcinoma
GB9721746D0 (en) Compositions
ZA937558B (en) New taxane derivatives, their preparation and pharmaceutical compositions which contain them
AU4830097A (en) Use of an extract of Cimicifuga
GEP20012517B (en) Taxoids, Method for Their Preparation and Pharmaceutical Compositions Containing Same
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired